-

Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera’s management will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Thursday, May 30, 2024 at 8:40 a.m. PT (11:40 a.m. ET).

A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference.

About Natera

Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 200 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-405-4709, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Industry:

Natera, Inc.

NASDAQ:NTRA
Release Versions
English

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-405-4709, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company’s non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications. Preeclampsia affects approximately 5-8% of pregnancies and remains a leading cause of maternal and neonatal morbidity.1 While clinical guidelines re...

Natera Submits Signatera™ CDx PMA to FDA

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx for detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with atezolizumab (Tecentriq®). This submission is supported by data from the randomized, double-blind, phase 3 IMvi...

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera’s Prospera Heart test can replace routine invasive biopsies for rejection monitoring in heart transplant recipients. Positive results would support a fundamental shift in the standard of care for heart transplant recipients away from invasive tissue sampling...
Back to Newsroom